Skip to content
Medical Health Aged Care

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

Medisca 2 mins read

Medisca today announced that Founder and Chairman Antonio Dos Santos has returned to the role of Chief Executive Officer as the company enters its next chapter of growth.


MONTREAL--BUSINESS WIRE--

For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day.

"When I founded Medisca, my vision was to raise the standard of pharmaceutical compounding by bringing pharmaceutical-grade quality to the industry and giving healthcare professionals access to the products, knowledge, and innovation they needed to deliver better patient care," said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. "That purpose continues to guide us. As we begin this next chapter, we'll keep investing in our people, our partnerships, and the innovation that will help shape the future of Medisca and the pharmaceutical compounding industry."

Working alongside Vice-Chair Maria Zaccardo and Medisca's C-Suite, Dos Santos will continue to guide the company's strategic direction as Medisca continues to expand globally and invest in its long-term growth.

For over three decades, Medisca has grown by staying true to its purpose while continuing to evolve with the needs of healthcare professionals,” said Maria Zaccardo, Vice-Chair of Medisca. “As we look ahead, we remain focused on supporting our customers, investing in our people, and continuing to strengthen Medisca for the future.”

As part of this leadership transition, Sanjay Goorachurn has stepped down from his role as Chief Executive Officer. Medisca thanks Sanjay for his dedication and contributions to the organization and wishes him continued success.

As Medisca continues to grow globally, the company remains committed to empowering personalized wellness for all by expanding the products, technologies, education, and expertise that help healthcare professionals deliver better patient care around the world.

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.Medisca.com and follow us on LinkedIn, Facebook, and YouTube.


Contact details:

Medisca Communications
[email protected]
1-800-665-6334

Media

More from this category

  • Medical Health Aged Care
  • 30/06/2026
  • 04:30
The Australian Nursing and Midwifery Federation (ANMF)

Nurses and midwives showcase innovative healthcare solutions

The Australian Nursing and Midwifery Federation (ANMF) will join nursing and midwifery leaders from across the country at Parliament Housetoday (Tuesday30 June),for a ‘hands on’demonstration ofthe high-quality, clinical capabilitiesof Australia's largest health workforce. TheParliamentary Friends of Nursingevent in the Mural Hall,will highlight the growing role of nurses and midwives in deliveringtimely, effective health care across the community, enabling people to accesshigh-qualitycare,when and where they need it. ANMF Federal Secretary Annie Butler saidtheevent willdemonstratenurse and midwife-led models of carethatdemonstrate the impact they can have on health outcomes when nurses and midwives work to their full scope of practice. “Nurses and midwives…

  • Medical Health Aged Care
  • 29/06/2026
  • 23:17
Optimi Health Corp.

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.The shipment included 1,000 capsules of 5mg psilocybin, which are being prescribed in Australia…

  • Medical Health Aged Care
  • 29/06/2026
  • 22:47
Kyowa Kirin

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in Montreal, CanadaPRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced positive results from PROSPER, a real-world observational study of mogamulizumab in adults with mycosis fungoides (MF) or Sézary syndrome (SS). In the study, patients reported clinically meaningful improvements in skin symptoms (itch, flaking, and redness) and body temperature regulation as early as week 4, with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.